Celgene Has Emerged As An Attractive Buy Opportunity In 2018 [Seeking Alpha]
bluebird bio, Inc. (BLUE)
Last bluebird bio, inc. earnings: 2/18 04:05 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.bluebirdbio.com/investor-overview
Company Research
Source: Seeking Alpha
Summary The last year has been pretty harsh for Celgene ( CELG ), as concerns related to Revlimid's patent expiry have gradually mounted. And these worries have eclipsed the investor sentiment to this extent that people seem to have forgotten some very basic facts about Celgene. The concerns about Revlimid are definitely overexaggerated, even though the composition of matter patent of the drug expires in October 2019 . This is because, for this drug, most of the polymorph patents extend up to 2022 and are at least as important as the composition of matter patent for thwarting generic competition for Revlimid. We also have two of the drug’s polymorph patents extending all the way up to 2027 (linked above). Then again, there is more to Celgene than Revlimid and we have exceptional products such as Pomalyst, Abraxane, and Otezla. We also have the company boasting of a very robust organically and inorganically grown research pipeline. In this series, I will delve deeper on
Show less
Read more
Impact Snapshot
Event Time:
BLUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
BLUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
BLUE alerts
High impacting bluebird bio, Inc. news events
Weekly update
A roundup of the hottest topics
BLUE
News
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- bluebird bio, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - BLUEAccesswire
- Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against bluebird bio, Inc. (BLUE)GlobeNewswire
- bluebird bio, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before May 28, 2024 to Discuss Your Rights - BLUEAccesswire
- bluebird bio, Inc. Class Action: Levi & Korsinsky Reminds bluebird bio Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of May 28, 2024 - BLUEAccesswire
BLUE
Earnings
- 11/7/23 - Beat
BLUE
Sec Filings
- 5/9/24 - Form 8-K
- 5/3/24 - Form 8-K
- 4/26/24 - Form 8-K
- BLUE's page on the SEC website